Status and phase
Conditions
Treatments
About
This was a prospective, open label, multicenter study evaluating the safety, tolerability and pharmacokinetics of CetuGEX™ after intravenous administration in patients with EGFR positive, locally advanced and/or metastatic solid cancers. The effect of CetuGEX™ on the development of anti-drug antibodies and on tumour response was also evaluated.
Full description
Male or female patients ≥18 years of age with a histologically confirmed locally advanced and/or metastatic solid organ tumor. Patients enrolled in Germany were required to have a positive EGFR overexpression status. Patients must have experienced a failure or non-availability of standard therapy (had received at least one line of chemotherapy and further standard therapy was not an option at study entry). Open-label, non-randomized, inter-patient dose-escalation, multi-center study. Patients were to receive CetuGEX until disease progression or until intolerable toxicities occurred.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male or female and age ≥ 18 yrs
Histologically confirmed EGFR positive locally advanced and/or metastatic solid organ tumour
Measurable or non-measurable tumour
Failure of standard therapy or non-availability of standard therapy (Patients must have received at least 1 line of chemotherapy and further standard therapy is not an option at study entry)
All anti-tumour therapies must be completed 4 weeks before start of study treatment; treatment with Cetuximab must be completed at least 6 weeks prior to study start
ECOG Performance Status ≤1 and estimated life expectancy of ≥ 3 months
Adequate organ function:
Patients of both genders with procreative potential must use effective contraception while enrolled in the study and for at least 4 weeks after the last study drug infusion
Written informed consent must be obtained prior to conducting any study-specific procedures
For Expansion Phase only:
No prior treatment with Cetuximab allowed
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
41 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal